[go: up one dir, main page]

AU2001261528A1 - Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg) - Google Patents

Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)

Info

Publication number
AU2001261528A1
AU2001261528A1 AU2001261528A AU6152801A AU2001261528A1 AU 2001261528 A1 AU2001261528 A1 AU 2001261528A1 AU 2001261528 A AU2001261528 A AU 2001261528A AU 6152801 A AU6152801 A AU 6152801A AU 2001261528 A1 AU2001261528 A1 AU 2001261528A1
Authority
AU
Australia
Prior art keywords
pttg
regulating
expression
methods
pituitary tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261528A
Inventor
Anthony P. Heaney
Gregory A. Horwitz
Hiroki Ishikawa
Shlomo Melmed
Run Yu
Xun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/569,956 external-priority patent/US6894031B1/en
Priority claimed from US09/730,469 external-priority patent/US20030018001A1/en
Priority claimed from US09/777,422 external-priority patent/US20020147162A1/en
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2001261528A1 publication Critical patent/AU2001261528A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001261528A 2000-05-12 2001-05-12 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg) Abandoned AU2001261528A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US09/569,956 US6894031B1 (en) 1996-11-21 2000-05-12 Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US09/569,956 2000-05-12
US68791100A 2000-10-13 2000-10-13
US09/687,911 2000-10-13
US09/730,469 2000-12-04
US09/730,469 US20030018001A1 (en) 1996-11-21 2000-12-04 Methods of using pituitary tumor transforming gene (PTTG) carboxy-terminal peptides to inhibit neoplastic cellular proliferation and/or transformation of breast and ovarian cells
US09/777,422 2001-02-05
US09/777,422 US20020147162A1 (en) 1996-11-21 2001-02-05 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (PTTG)
US09/854,326 US6913926B2 (en) 1996-11-21 2001-05-11 Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
US09/854,326 2001-05-11
PCT/US2001/015437 WO2001087935A2 (en) 2000-05-12 2001-05-12 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)

Publications (1)

Publication Number Publication Date
AU2001261528A1 true AU2001261528A1 (en) 2001-11-26

Family

ID=27541918

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001261529A Abandoned AU2001261529A1 (en) 2000-05-12 2001-05-12 Modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (pttg) expression and/or function
AU2001261528A Abandoned AU2001261528A1 (en) 2000-05-12 2001-05-12 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001261529A Abandoned AU2001261529A1 (en) 2000-05-12 2001-05-12 Modulating activation of lymphocytes and screening potential immunomodulating agents by targeting pituitary tumor transforming gene (pttg) expression and/or function

Country Status (5)

Country Link
US (1) US6913926B2 (en)
EP (3) EP1280906A2 (en)
JP (2) JP2004526404A (en)
AU (2) AU2001261529A1 (en)
WO (3) WO2001087039A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20060047414A1 (en) * 2004-09-02 2006-03-02 Matsushita Electric Industrial Co., Ltd. Probe-car system using beacon and apparatus therefore
KR100627377B1 (en) 2005-03-04 2006-09-25 한국생명공학연구원 Gene therapy of cancer using a small interfering RNA and a vector expressing the same, which may block the synthesis of pituitary tumor-transforming gene 1 protein
US8822364B2 (en) 2011-04-19 2014-09-02 Cummins Inc. Method for treating a platinum contaminated catalytic component
WO2019132594A1 (en) * 2017-12-29 2019-07-04 한양대학교 산학협력단 Cell sheet for gene delivery
WO2025069023A1 (en) * 2023-09-27 2025-04-03 Ofek - Eshkolot Research And Development Ltd. Phosphorothioate dna (psdna) and/or phosphodiester dna (podna) and/or other materials to treat cancer and/or neurodegenerative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009442A1 (en) 1989-02-08 1990-08-23 Uab Research Foundation Antiproliferation factor
AU4535893A (en) * 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
US5972901A (en) * 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US6077835A (en) * 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
DE69535853D1 (en) * 1994-03-23 2008-11-20 Univ Case Western Reserve COMPACT NUCLEIC ACID AND THEIR ADMINISTRATION IN CELLS
JPH07322892A (en) 1994-05-30 1995-12-12 Tonen Corp Method for screening immunosuppressive substance
JPH09173053A (en) 1995-12-27 1997-07-08 Tonen Corp Immunosuppressant hypersensitive yeast mutant and use thereof
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
WO1998022587A2 (en) 1996-11-21 1998-05-28 Cedars-Sinai Medical Center Pituitary-tumor-transforming-genes, and related products
US6436656B1 (en) 1997-03-03 2002-08-20 Duke University Method for screening a test compound for potential as an immunosuppressive drug candidate

Also Published As

Publication number Publication date
EP1280907A2 (en) 2003-02-05
WO2001088116A9 (en) 2002-06-06
WO2001087935A2 (en) 2001-11-22
WO2001087935A9 (en) 2002-12-27
EP1280906A2 (en) 2003-02-05
WO2001087039A2 (en) 2001-11-22
JP2004526404A (en) 2004-09-02
WO2001087935A3 (en) 2002-08-08
WO2001088116A3 (en) 2002-05-10
AU2001261529A1 (en) 2001-11-26
WO2001088116A2 (en) 2001-11-22
JP2003533988A (en) 2003-11-18
EP1280908A2 (en) 2003-02-05
US20030186902A1 (en) 2003-10-02
WO2001087039A3 (en) 2002-03-21
US6913926B2 (en) 2005-07-05

Similar Documents

Publication Publication Date Title
AU2002365825A1 (en) Modulation control
AU7357098A (en) Rapid production of autologous tumor vaccines by using hsv amplicon vectors
AU3811597A (en) Methods and devices for controlling the reaction by adjusting the oxidant consumption rate
AUPR551801A0 (en) Floatation disk for paint (2)
AU2002330853A1 (en) Control line assembly for kites
AU2003234613A1 (en) Method of modulating angiogenesis
AU2002316896A1 (en) Method for the production of nanodispersions
AU2003268096A1 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
AU2001290127A1 (en) Control of hydrocarbon wells
AU2001261528A1 (en) Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
AU2002324787A1 (en) Modulation of angiogenesis by a-beta peptides
AU2001293463A1 (en) Device for the control of functions by means of biometric data
AU2002328920A1 (en) Emulsifier mixture
AU2001285349A1 (en) Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
AU2002322911A1 (en) Use of alphacp1, alphacp2, and hur for modulating gene expression and inducing angiogenesis
AU2001261343A1 (en) Method of regulating angiogenesis using ryk protein
AU3628699A (en) Transcription factors regulating the expression of ethylene-inducible genes
AU2001263059A1 (en) Method of regulating biological activity of pituitary tumor transforming gene (pttg)1 using pttg2
AUPR253901A0 (en) Emulsifier
AU2002246829A1 (en) Methods to control the host range of retroviral vectors
AU2001291934A1 (en) Means for regulating immune defences
AU2003217229A1 (en) Methods of modulating angiogenesis
AU2002325821A1 (en) Method for treating diabetes based on the modulation of nh4alpha gene expression
AU2002341548A1 (en) Antisense modulation of transforming growth factor-beta 3 expression
AU2002306951A1 (en) Gene regulation ii